Patent Application
20070178546
This application claims priority to European application EP 05026822.6 filed Dec. 8, 2005.
The present invention relates to the field of measuring enzymatic activities in biological samples. More specifically, it relates to the use of a polar organic solvent for the stabilization of a cholinesterase substrate solution, and to the use of said solution for determining the activity of cholinesterase in a sample. Furthermore, methods and kits for determining the activity of cholinesterase are provided.
Cholinesterase is the common name for an enzymatic activity, which catalyzes the hydrolysis of an acylester to an alcohol and a carboxylate. Cholinesterases act on a variety of substrates with alcohol moieties such as phenyl-, indoxyl-alcohols, and preferably choline and with carboxylate moieties such as carbonic, dicarbonic and benzoic acids (Brown et al., Adv. Clin. Chem., 22:1-123 (1981)). Based on their specificity towards carboxylate moieties, cholinesterases are subdivided into two groups. The “true cholinesterases” or acetylcholinesterases (acetylcholine acetylhydrolase, EC 3.1.1.7) show a marked selectivity for acetyl moieties, whereas the “pseudocholinesterases” or acylcholinesterases (acylcholine acylhydrolase, EC 3.1.1.8) preferably hydrolyze substrates with bigger carboxylate moieties such as butyryl or benzoyl.
Acetylcholinesterase plays a most important role in signal transduction within the nervous system and between nerve and muscle. It is also present in erythrocytes. The enzyme is irreversibly inactivated by nerve gases such as sarin, but also in insecticide poisoning.
The biological function of acylcholinesterase is unknown. Acylcholinesterase can be found in pancreas, heart, intestinal mucosa, serum, in the white brain substance and in liver.
Cholinesterases and the determination of their activity particularly has become of clinical interest. Due to its obvious hepatic origin, this mainly applies to acylcholinesterase. Detected as an index of liver function, the enzyme is also used as a clinical indicator for suspected insecticide toxication. By a preoperative screening for acylcholinesterase, patients with atypical forms of the enzyme can be identified aiming at preventing a prolonged apnea, which is caused by a delayed degradation of muscle relaxans. Decreased levels of acylcholinesterase can be found in connection with toxications by phospho-organic compounds, hepatitis, cirrhosis, myocardial infarct, acute infections and with atypical phenotypes of the enzyme.
Methods for the detection of cholinesterase activity in biological samples are described in the prior art (Burtis and Ashwood (eds.), Tietz Fundamentals of Clinical Chemistry, 4th Ed., ISBN 0-7216-3763-9). The common test principle is based on the use of thiocholine esters such as acetylthiocholine, propionylthiocholine, butyrylthiocholine and succinylbisthiocholine. Among those, only acetyl- and propionylthiocholine are useful in the determination of acetylcholinesterase. Serum acylcholinesterase, although active against all these substrates, is preferably determined using succinylbisthiocholine and especially butyrylthiocholine. All these thioesters are unstable in aqueous solution because of hydrolysis of the thioester bond. The low stabilities of refrigerated reagent solutions have been well established by several authors, e.g. acetylthiocholine, 7 days (Whittaker M. Cholinesterases. In: Bergmeyer H U, ed; Methods of Enzymatic Analyses, 3rd edition, Weinheim Verlag Chemie, 1984:52-74); propionylthiocholine, 1 day (Dietz et al. Colorimetric Determination of Serum Cholinesterase and Its Genetic Variance by the Propionylthiocholine-Dithiobis(nitrobenzoic Acid) Procedure. Clinical Chemistry 1973; 19:1309-1313); butyrylthiocholine, 30 days (Schmidt E. et al. Proposal of Standard Methods for the Determination of Enzyme Catalytic Concentrations in Serum and Plasma at 37° C. Eur. J. Clin. Chem. Clin. Biochem. 1992; 30:163-170). While some of the aforementioned substrates of acylcholinesterase are also split by acetylcholinesterase, arylesterase (arylester hydrolase, EC 3.1.1.2), and even albumin, butyrylthiocholine (BTC; Knedel and Böttger, Klin Wschr 45:325-327 (1967)) does not suffer from those drawbacks. Thus BTC is generally regarded as one of the most specific substrates and was chosen for national recommended cholinesterase assay methods (Association of Clinical Biochemists, News Sheet Assoc. Clin. Biochemists, Suppl. 202:31s-36s (1980); Cholinesterase, In: Kommentare zum Arzneibuch der Deutschen Demokratischen Republik, Heft 2: Enzym-Aktivitäsbestimmung in der Laboratoriumsdiagnostik, Akademie-Verlag, Berlin, 56-65 (1988)). Dependent on acylcholinesterase activity, BTC is hydrolyzed to thiocholine and butyrate. Thiocholine reacts with 5,5′-dithiobis-2-nitrobenzoate (DTNB) leading to the formation of the yellow dye 5-mercapto-2-nitrobenzoate.
The formation rate of 5-mercapto-2-nitrobenzoate is directly proportional to the catalytic activity of the acylcholinesterase, which is determined according to the increase in the extinction at a wavelength of 480 nm. Due to the specificity of the substrate, the test performed with serum is not interfered by acetylcholinesterase, which is released from erythrocytes because of marginal hemolysis.
In another acylcholinesterase assay, the test principle by Knedel and Böttger, Klin. Wschr. 45:325-327 (1967) is modified in that thiocholine as product of the acylcholinesterase-driven reaction instantaneously reduces yellow hexacyanoferrate (III) to almost colorless hexacyanoferrate (II), thus also allowing the direct spectrometric monitoring of the reaction.
Optimized reaction conditions for measuring the catalytic activity of acylcholinesterase in human sera have been investigated and established (Schmidt et al., Eur. J. Clin. Chem. Clin. Biochem. 30(3): 163-170 (1992)). These conditions consider both the enzyme kinetics and the technical aspects of manual and mechanized performance. They do not necessarily provide maximum possible conversion rates, but only the highest available robustness of the method.
However, an essential and yet unsolved problem is the low stability of BTC, since butyrylthiocholine as a thioester compound is prone to autohydrolysis. Consequently, the spontaneous cleavage of BTC under assay conditions always has to be subtracted from the turnover of BTC to get the real acylcholinesterase activity. It is known that this reagent blank reaction can be minimized to a certain extent by optimizing substrate concentration and buffer conditions. Since the stability of BTC in solution significantly decreases with increasing storage time, an essential prerequisite thereby is the provision of a freshly prepared BTC solution. At present this can only be achieved by the reconstitution of a BTC granulate, a process which is intricate and time-consuming.
There is no reagent available in the prior art, which allows the storage of dissolved cholinesterase substrates such as BTC over a longer time period in absence of any enzyme without having an increasing autohydrolysis activity. Due to the need to provide a freshly dissolved substrate in order to minimize the reagent blank reaction in a cholinesterase assay, a detection of cholinesterase activities in a larger set of samples in parallel would be complex and ineffective. A simple and effective detection of cholinesterase activities in numerous samples, e.g. by performing a high throughput process in an automated analyzer, is not possible at the time.
Hence, the technical problem underlying the present invention is to provide a stabilized cholinesterase substrate solution.
The object of the present invention is a stabilized cholinesterase substrate solution, wherein at least one substrate is stabilized by at least one species of a polar organic solvent.
The present invention also relates to the use of a stabilized cholinesterase substrate solution, wherein at least one substrate is stabilized by at least one species of a polar organic solvent. The invention further relates to the use of a polar organic solvent for the stabilization of a cholinesterase substrate solution, wherein at least one substrate is stabilized by at least one species of a polar organic solvent in a buffered solution. Also within the scope of the present invention is a stabilized cholinesterase substrate solution for determining the activity of a cholinesterase in a sample, wherein at least one substrate is stabilized by at least one species of a polar organic solvent.
Furthermore, the invention relates to a method for determining the activity of a cholinesterase in a sample, comprising the steps of combining a sample suspected of containing the enzyme under conditions suitable for enzymatic activity and a reagent comprising a stabilized cholinesterase substrate solution, wherein at least one substrate is stabilized by at least one species of a polar organic solvent, and of monitoring the activity of the enzyme.
Within the scope of the present invention is a kit for determining the activity of a cholinesterase in a sample comprising in a packaged combination a first reagent comprising a buffer solution suitable for the activity of cholinesterase, and a second reagent comprising a stabilized cholinesterase substrate solution, wherein at least one substrate is stabilized by at least one species of a polar organic solvent. Also within the scope of the present invention is a kit for conducting a method for determining the activity of a cholinesterase in a sample, the method comprising the steps of combining a sample suspected of containing the enzyme under conditions suitable for enzymatic activity and a reagent comprising a stabilized cholinesterase substrate solution, wherein at least one substrate is stabilized by at least one species of a polar organic solvent, and of monitoring the activity of the enzyme.
Surprisingly, it has been found that the combination of at least one cholinesterase substrate with at least one species of a polar organic solvent results in a cholinesterase substrate solution, which is stabilized. Accordingly, the present invention provides a stabilized cholinesterase substrate solution, wherein at least one substrate is stabilized by at least one species of a polar organic solvent.
The term “stabilized” means that the cholinesterase substrate solution according to the present invention can be stored in absence of any enzyme activity without a significant inactivation of the substrate.
“Without a significant inactivation of the substrate” means that e.g. after a storage of the stabilized solution at 35° C. over a time period of at least 18 days or after a storage under typical laboratory conditions, that is refrigerated at 4-8° C. for a time period of at least 15 months no loss of BTC has occurred, resulting in an intercept of about <+/−300 U/l and a slope <+/−3% of a straight-line in a plot of CHE catalytic concentration obtained using freshly prepared and incubated substrate solution.
The term “cholinesterase” comprises an enzymatic activity, which catalyzes the hydrolysis of an acylester to an alcohol and a carboxylate. In the scope of the present invention any cholinesterase is comprised, preferably acetylcholinesterase as defined by EC 3.1.1.7 or acylcholinesterase as defined by EC 3.1.1.8. It is also to be understood that “cholinesterase” is meant to cover cholinesterase as well as its biologically active subforms, fragments and subunits, which behave in a biological sense, i.e. via hydrolyzation of an acylester to an alcohol and a carboxylate, as cholinesterase.
A stabilized cholinesterase substrate solution according to the invention has striking advantages in comparison with the hitherto known cholinesterase substrate solutions which have to be reconstituted from granulates prior to application. Being a liquid reagent, for a stabilized substrate solution according to the invention there is not any longer a need for the reconstitution from a granulate. This is an essential prerequisite for a constant accuracy of the detection of cholinesterase activity. A reconstitution, i.e. bringing granulate in solution is usually time consuming and error-prone. After each reconstitution, an additional calibration assay has to be performed to verify experimental data obtained with independently reconstituted substrate solutions. In contrast, the provision of a stabilized cholinesterase substrate solution allows the homogeneity of the composition over all bottles of a reagent lot thereby guaranteeing an improvement of accuracy and a reduction of the number of calibration assays.
In an embodiment of the present invention the stabilized cholinesterase substrate solution is a stabilized acylcholinesterase substrate solution. In another embodiment of the present invention the stabilized cholinesterase substrate solution is a stabilized acetylcholinesterase substrate solution.
The term “cholinesterase substrate” comprises all substrates, which are hydrolyzed by cholinesterase, comprising substrates belonging to the class of acyl esters. In an embodiment of the present invention the at least one substrate of a stabilized cholinesterase substrate solution is a choline ester. In another embodiment the at least one substrate of the stabilized cholinesterase substrate solution is a thioester, preferably butyrylthiocholine (BTC) or acetylthiocholine (ATC).
The term “polar organic solvent” refers to solvents consisting of organic compounds, which contain carbon atoms and which have hydrophilic properties due to unequally distributed electric charges in the organic compounds, leaving one end of each molecule more positive than the other. In an embodiment of the present invention said at least one species of a polar organic solvent is a polar protic organic solvent. The term “polar protic organic solvent” refers to organic solvents, the organic compounds of which contain, in contrast to a “polar aprotic organic solvent”, one or more acidic hydrogen atoms. In a preferred embodiment of the invention, said at least one species of a polar protic organic solvent is an alcohol.
The term “alcohol” refers to univalent alcohols, i.e. alcohols with only one hydroxyl group, as well as to polyvalent alcohols containing more than one hydroxyl group. Preferably the at least one species of a polar protic organic solvent is an alcohol selected from the group with a chain length between 1 and 7 carbon atoms. In the scope of the present invention, alcohols with a chain length between 1 and 7 carbon atoms comprise alcohols with a branched carbon chain such as 3-Methylhexan-3-ol as well as alcohols with a linear carbon chain such as ethanol. In a preferred embodiment of the present invention, the stabilized cholinesterase substrate solution is characterized in that at least one substrate is stabilized by an alcohol selected from the group consisting of methanol, ethanol, propanol, and isopropanol. In another preferred embodiment of the invention, the stabilized cholinesterase substrate solution is stabilized by glycerin.
According to the present invention, said at least one species of a polar organic solvent may also comprise a carboxylic acid. The term “carboxylic acid” refers to organic acids characterized by the presence of a carboxyl group. “Carboxylic acid” also comprises the salts and anions of carboxylic acids, which are called carboxylates, as well as carboxylic acids having two or more carboxylic acid groups per molecule.
In an embodiment of the present invention said at least one species of a polar organic solvent is a polar aprotic organic solvent, preferably selected from the group consisting of carbonyl compounds or heterocarbonyl compounds. In a more preferred embodiment of the invention, said carbonyl compound or heterocarbonyl compound is selected from the group containing 1 to 12 carbon atoms. In another preferred embodiment of the present invention, the stabilized cholinesterase substrate solution is characterized in that at least one substrate is stabilized by a carbonyl compound or a heterocarbonyl compound selected from the group consisting of dimethylsulfoxide (DMSO), dimethylformamide (DMF), acetone, acetylacetone, acetonitrile and hexamethylphosphoric triamide (HMPT).
In another preferred embodiment of the present invention, said at least one species of a polar aprotic organic solvent is an ether. The term “ether” refers to a class of chemical compounds which contain an ether group i.e. an oxygen atom connected to two substituted alkyl groups. In a more preferred embodiment of the present invention, the stabilized cholinesterase substrate solution is characterized in that at least one substrate is stabilized by an ether selected from the group containing 1 to 12 carbon atoms. In the scope of the present invention, any ether containing 1 to 12 carbon atoms is comprised, e.g. cyclic ether as well as ether having branched or linear carbon chains. In an embodiment of the present invention, the stabilized cholinesterase substrate solution is characterized in that at least one substrate is stabilized by a cyclic ether, preferably tetrahydrofuran (THF) or dioxan.
Also within the scope of the present invention is a stabilized cholinesterase substrate solution, wherein the concentration of at least one species of a polar organic solvent in that reaction mixture is at least 0.25 volume percent and maximal 100 volume percent.
In a preferred embodiment of the present invention, the concentration of the at least one species of a polar organic solvent in a stabilized cholinesterase substrate solution is for DMSO at least 0.25 volume percent and maximal 100 volume percent, preferably at least 0.25 volume percent and maximal 20 volume percent, for ethanol at least 0.25 volume percent and maximal 100 volume percent, preferably at least 0.25 volume percent and maximal 20 volume percent, for isopropanol at least 0.5 volume percent and maximal 95 volume percent, preferably at least 0.5 volume percent and maximal 20 volume percent, and/or for THF at least 0.5 volume percent and maximal 100 volume percent, preferably at least 0.5 volume percent and maximal 20 volume percent.
Another aspect of the present invention is the use of a stabilized cholinesterase substrate solution, wherein at least one substrate is stabilized by at least one species of a polar organic solvent. A further aspect of the present invention is the use of a polar organic solvent for the stabilization of a cholinesterase substrate solution, wherein at least one substrate is stabilized by at least one species of a polar organic solvent in a buffered solution. Also within the scope of the present invention is a stabilized cholinesterase substrate solution for determining the activity of a cholinesterase in a sample, wherein at least one substrate is stabilized by at least one species of a polar organic solvent.
The term “sample” refers to any sample suspected of containing cholinesterase. The sample is typically an aqueous solution. In an embodiment of the present invention, the sample is a biological sample, such as a body fluid from a host, for example, urine, whole blood, plasma, serum, saliva, semen, stool, sputum, cerebral spinal fluid, tears, mucus or the like, but preferably is plasma or serum. The sample can be pretreated if desired and can be prepared in any convenient medium that does not interfere with the assay. An aqueous medium is preferred.
The activity of cholinesterase can be determined by quantitative, semi-quantitative and qualitative methods, as well as by all other methods for determining cholinesterase. For example, a method that merely detects the presence or absence of cholinesterase in a sample suspected of containing cholinesterase is considered to be included within the scope of the present invention. The terms “detecting”, “monitoring” and “measuring”, as well as other common synonyms for determining, are contemplated within the scope of the present invention.
The determination of cholinesterase activity according to the present invention may be conducted by a rate-assay method wherein change in absorbance of a product of the cholinesterase activity per unit time is measured or by end-point method wherein the reaction is quenched after a certain period of time has elapsed. According to the present invention the determination of cholinesterase activity also may be conducted by measuring change in absorbance of a product, which results from a secondary reaction starting from one of the products of the actual enzymatic reaction. The method can easily be applied to automated analyzers for laboratory or clinical analysis. In an embodiment of the present invention the monitoring of the activity of cholinesterase is conducted by determining the formation of thiocholine, preferably by measuring the reduction of hexacyanoferrate (III) to hexacyanoferrate (II) by spectrophotometry. In another preferred embodiment of the present invention, the cholinesterase-dependent formation of thiocholine is determined by measuring the formation of 5-mercapto-2-nitrobenzoate as a product of the reaction of thiocholine with 5,5′-dithiobis-2-nitrobenzoate by spectrophotometry. According to the present invention, the monitoring of the activity of cholinesterase may be conducted by using an automated analyzer.
Also within the scope of the present invention is a method for determining the activity of a cholinesterase in a sample, comprising the steps of combining a sample suspected of containing the enzyme under conditions suitable for enzymatic activity and a reagent comprising a stabilized cholinesterase substrate solution, wherein at least one substrate is stabilized by at least one species of a polar organic solvent, and of monitoring the activity of the enzyme.
To enhance the versatility of the invention, reagents useful in the methods of the invention can be provided in a packaged combination, in the same or in separate containers, in liquid or in lyophilized form so that the ratio of the reagents provides for substantial optimization of the method and assay. The reagents may each be in separate containers or various reagents can be combined in one or more containers depending on the cross-reactivity and the stability of the reagents. Accordingly, one aspect of the present invention relates to kits useful to conveniently performing the assay methods of the invention for the determination of the cholinesterase activity.
Within the scope of the present is a kit for determining the activity of a cholinesterase in a sample comprising in a packaged combination a first reagent comprising a buffer solution suitable for the activity of cholinesterase, and a second reagent comprising a stabilized cholinesterase substrate solution, wherein at least one substrate is stabilized by at least one species of a polar organic solvent. Also within the scope of the present invention is a kit for conducting a method for determining the activity of a cholinesterase in a sample, the method comprising the steps of combining a sample suspected of containing the enzyme under conditions suitable for enzymatic activity and a reagent comprising a stabilized cholinesterase substrate solution, wherein at least one substrate is stabilized by at least one species of a polar organic solvent, and of monitoring the activity of the enzyme. In an embodiment of the present invention, said kit for conducting said method for determining the activity of a cholinesterase in a sample comprises in a packaged combination a first reagent comprising a buffer solution suitable for the activity of cholinesterase, and a second reagent comprising a stabilized cholinesterase substrate solution, wherein at least one substrate is stabilized by at least one species of a polar organic solvent.
The reagents may remain in liquid form or lyophilized. The kit can further comprise other packaged calibration materials, such as a calibration reagent comprising a known amount of cholinesterase. Calibration material means any standard or reference material containing a known amount of the analyte to be measured. The sample suspected of containing the analyte and the calibration material are assayed under similar conditions. Analyte concentration is then calculated by comparing the results obtained for the unknown specimen with results obtained for the standard. In a preferred embodiment, the kit comprises a buffer solution optimized for cholinesterase activity and a cholinesterase substrate solution stabilized by at least 0.25 volume percent and maximal 100 volume percent of DMSO, at least 0.25 volume percent and maximal 100 volume percent of ethanol, at least 0.5 volume percent and maximal 95 volume percent of isopropanol an/or at least 0.5 volume percent and maximal 100 volume percent of THF. In another preferred embodiment of the present invention, the kit comprises a buffer solution optimized for cholinesterase activity and a cholinesterase substrate solution stabilized by at least 0.25 volume percent and maximal 20 volume percent of DMSO, at least 0.25 volume percent and maximal 20 volume percent of ethanol, at least 0.5 volume percent and maximal 20volume percent of isopropanol and/or at least 0.5 volume percent and maximal 20 volume percent of THF.
Various ancillary material will frequently be employed in a substrate solution or in an assay in accordance with the present invention. For example, buffers will normally be present in the assay medium, as well as stabilizers for the assay medium and the assay components. Frequently, in addition to these additives, additional proteins may be included, such as albumin, or surfactants, particularly non-ionic surfactants, or the like.
The present invention is now described in more detail with the following examples or figures to which it is of course not limited.
Determination of cholinesterase (CHE) activity was based on the formation and detection of thiocholine according to the following reaction scheme:
Dependent on the cholinesterase activity, thiocholine is specifically liberated from butyrylthiocholine. Thiocholine instantaneously reduces yellow hexacyanoferrate III to almost colorless hexacyanoferrate II. The decrease of extinction can be spectrophotometrically measured at a wavelength of 405 nm and a temperature of 37° C. The cholinesterase concentration is calculated with the molar absorption coefficient of potassium hexacyanoferrate III (92.7+/−0.4 m2/mol).
In particular the determination of cholinesterase activity was performed as follows:
Two reagent solutions, R1 and R2 were freshly prepared:
Serum, heparin or EDTA plasma as sample material or 0.9% (w/v) NaCl, R1 and R2 were pipetted into a cuvette according to the scheme below, resulting in a final concentration of 75.2 mM pyrophosphate, 2.0 mM hexacyanoferrate (III), 7.5 mM butyrylthiocholine and 1.6 mM HEPPS.
All reagents and solutions mentioned were used as 37° C. tempered working solutions. Accordingly the temperature of the mixture in the cuvette again was controlled to assure a temperature of 37±0.05° C. after pipetting.
Then 180 μl R2 was added and the reaction was started by thoroughly mixing the sample.
Using a manual photometer, the spectrophotometric measurement was performed exactly 90, 120, 150 and 180 sec after addition of R2 according to the following conditions:
Further, the following dilution limit for the sample material was taken into account:
ΔE/min=0.380 (measuring time: 60 sec)
In case of higher activities 100 μl of the sample was mixed with 100 μl 0.9% (w/v) NaCl-solution, the measurement was repeated and the result was multiplied with factor 2.
In case of activities of ΔE/min<0.007, the sample volume was doubled (30 μl), the reagent blank was subtracted and the result multiplied with factor 33914.
The measurement was performed against air in order to determine a decrease of extinction. For each series of measurements values for blank reaction were determined 5 times and at any one time values for blank reactions were subtracted from the value of the actual enzymatic reaction.
Thus the turnover rate of cholinesterase in the sample equals the difference of the sample reaction and the blank reaction:
(ΔE/min)CHE=(ΔE/min) Sample−(ΔE/min) Reagent Blank
The catalytic concentration of cholinesterase (U/L) was calculated by multiplying the turnover rate (ΔE/min)CHE with the factor 78749:
U/L=78749 ΔECHE/min
The formula with the factor 78749 is based on the following calculation:
Insufficient stabilization of BTC could be seen in a change of the results by aging of the reagent. For the assessment of the BTC stability the catalytic concentration of cholinesterase obtained with tempered substrate solution (tempered at 35° C. for 18-21 days) was compared with that obtained with freshly prepared substrate solution.
Measurements were conducted on a Roche/Hitachi 917 analyzer analogous to the procedure described in example 1.
The above-mentioned “aging model” is appropriate to evaluate quickly different cholinesterase substrate solutions since a reagent tempered at 35° C. for 18-21 days corresponds to a reagent stored under refrigerated routine conditions for 15-18 months.
Using this “aging model” the stability of different cholinesterase substrate solutions −/+ certain polar organic solvents was determined according to the intercept and the slope of a straight-line in a plot of CHE catalytic concentrations obtained using freshly prepared and tempered substrate solution (see e.g.
These parameters (intercept and slope) were compared with the parameters of a not stabilized cholinesterase substrate solution, e.g. prepared as proposed by the DGKC (Deutsche Gesellschaft für Klinische Chemie, see Schmidt et al., Eur. J. Clin. Chem. Clin. Biochem. 30(3): 163-170 (1992) (see
Accordingly an intercept of about <+/−300 U/l and a slope <+/−3% were the criteria for a stabilized cholinesterase substrate solution indicating that there was virtually no loss of BTC during the incubation at 35° C. for 21 days.
In contrast, the values of these parameters analogously determined with the not stabilized original formulation as proposed by the DGKC or prepared according to Example 1 (i.e. R2 without polar organic solvent) differ significantly from those indicating stabilization of BTC:
The fresh reagent was calibrated with the Roche calibrator CFAS and the tempered reagent was read off the calibration curve of the fresh reagent.
Cholinesterase substrate solutions stabilized with the following polar organic solvents were tested and fulfill the requirements for the stabilization of BTC (each the concentration in volume percent is indicated in brackets):
Based on the “aging model” as described in Example 2 the minimal concentration (in volume percent) of a polar organic solvent was determined according to the intercept and the slope of a straight-line in a plot of CHE catalytic concentrations obtained using freshly prepared and tempered substrate solution.
Taking into account the criteria for a stabilized cholinesterase substrate solution, i.e. an intercept of about <+/−300 U/l and a slope <+/−3%, the lowest concentration with a stabilizing effect was 1% (volume percent) for each ethanol and DMSO, and 2% (volume percent) for each THF and Isopropanol.
From the data summarized in Table 2 it can be concluded that a stabilized solution of BTC can be prepared using 0.25% DMSO, 0.25% ethanol, 0.5% isopropanol and 0.5% THF.
Reagent R1 is prepared according to Example 1. Reagent R2 is prepared according to Example 1 including the polar organic solvents DMSO, 0.25%; ETOH, 0.25%; Isopropanol, 0.5%; THF, 0.5%. An aliquot of the freshly prepared R2 is stored at 35° C. for 21 days. Another aliquot is stored refrigerated at 4-8° C. After this aging period, both aliquots are used together with R1 in the determination of cholinesterase activity according to Example 1 for at least 30 samples with CHE activities between 3000 and 15000 U/l.
The plot of results with the aged R2 versus the R2 stored refrigerated is expected to give results indicating that there was virtually no loss of BTC according to the criteria for a stabilized cholinesterase substrate solution as defined above.
| Number | Date | Country | Kind |
|---|---|---|---|
| EP 05026822.6 | Dec 2005 | EP | regional |
